MyBiotics signs second option agreement with Ferring Holding for the validation

MyBiotics Pharma which is a microbiome therapeutics company announced that it has entered into second option agreement with Ferring Holding Ltd. for the validation of MyBiotics’ microbiome-based therapeutics in the field of women’s health.

MyBiotics has developed breakthrough and robust production and fermentation techniques for growing a highly stable and diverse bacterial community that can be delivered to the gut efficiently and can reliably restore microbiome equilibrium. The technology is highly potent and suitable for patients with medical indications related to the microbiome or for those who use antibiotics.

David Daboush, CEO of MyBiotics Pharma said “Our technology enables us to generate concentrated and effective bacterial raw material that can be introduced into the gastrointestinal tract and restore ecological equilibrium to the gut microbiota. Combining our innovative technology with the extensive drug development and marketing expertise of the Ferring Group has the potential to lead to novel treatments in the fields of gastroenterology and women’s health, offering patients long term relief without significant risks.”